Although snail paced in the development, the worlds two largest vaccine manufacturing giants France based Sanofi and UK based GlaxoSmithKline plc on Thursday morning announced that they entered the phase 1 and 2 of human clinical trials in the US.
The two pharma companies anticipated that they might fetch trial results by December, and are keen to start a Phase 3 trial subsequently. The company spokesperson said they expect to get FDA clearance for the vaccine in the first half of next year.
This joint project of Sanofi and GSK has a total of 440 healthy volunteers in the trials across 11 investigational sites in the US. The vaccine candidate is designed with Sanofi’s recombinant protein- based technology of seasonal influenza conjointly with pandemic adjuvant technology and aims to produce 1 billion doses in 2021.
Thomas Triomphe, executive vice president and global head of Sanofi Pasteur, said in a statement that their dedicated team are incessantly working and believe that the results of phase 1 and 2 will play a key role in proceeding to the third phase, possibly by the end of the year.
The US government granted $2.1 bn in July to boost up the vaccine development process, where the two pharma companies would provide US with 100 doses of the treatment.
The makers of Hari Hara Veera Mallu unveiled the teaser of the film today and…
In Tollywood film industry, the bond between director S.S. Rajamouli and actor Jr. NTR, fondly…
Anand Devarakonda is riding the wave of success from his recent film “Baby.” This coming-of-age…
There is a whole lot of emphasis on encouraging fresh talent in the Telugu film…
The much anticipated teaser of Pawan Kalyan’s Hari Hara Veera Mallu has been unveiled and…
Monopoly, the classic board game of buying, selling, and trading properties, has brought families and…